SpringerLink
Log in

Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Objective

To study the differences in the cardiometabolic profile between patients with non-functioning adrenal incidentalomas (NFAI) and incidentalomas with autonomous cortisol secretion (ACS).

Methods

A total of 149 patients with adrenal incidentalomas were retrospectively evaluated and followed-up for a mean time of 34.6 months at Departments of Endocrinology and Metabolic Diseases Units of four tertiary Spanish hospitals. Patients were grouped as NFAI or ACS adenomas based on two cutoffs in the dexamethasone suppression test (DST): 3.0 µg/dl (NFAIDST3 or ACSDST3) and 1.8 µg/dl (ACSDST1.8 and NFAIDST1.8).

Results

The mean age of both groups was 62.0 (10.31) and was similar in ACS and NFAI. The prevalence of diabetes, high blood pressure, cardiovascular, and cerebrovascular disease was higher in ACS than in NFAI, but differences only reached statistical significance for cerebrovascular disease using the 3.0 µg/dl cutoff (15.8% vs 2.3%, p = 0.01) and for diabetes using the 1.8 µg/dl cutoff (38.0% vs 22.0%, p = 0.04). No differences were found in the prevalence of dyslipidemia. The prevalence of obesity was lower in patients with ACS than in NFAI 26.3% vs 39.2%, p = 0.18 (NFAIDST3 vs ACSDST3) and 32.1% vs 40.6%, p = 0.56 (ACSDST1.8 vs NFAIDST1.8), but the differences did not reach statistical significance. Maximum adenoma diameter (R-squared = 0.15, p < 0.001) and cerebrovascular disease (OR = 1.59, p = 0.04) were the only parameters that could be predicted by the DST. The DST was an inadequate predictor of clinical (systolic and diastolic blood pressure, body mass index), hormonal (DHEAS, ACTH, UFC, and basal serum cortisol), biochemical (glucose, cholesterol, LDL, HDL, and triglycerides), and other radiological (laterality, lipid content) parameters. Throughout the follow-up, patients did not develop overt Cushing’s Syndrome; three NFAIDST3 developed ACSDST3, eight NFAIDST1.8 developed ACSDST1.8, and one NFAIDST1.8 progressed to ACSDST3. In both groups (NFAI and ACS) the metabolic profile remained stable.

Conclusions

Our data suggest higher prevalence of diabetes and cerebrovascular disease in ACS patients compared with NFAI. However, probably because of the small sample size, the differences only reached statistical significance using the cutoffs of 1.8 µg/dl for diabetes and 3.0 µg/dl for cerebrovascular disease. Patients with ACS and NFAI rarely progress to more aggressive forms of hypercortisolism, and the metabolic profile usually remains stable during the follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price, A. Sahdev et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175(2), G1–G34 (2016). https://doi.org/10.1530/EJE-16-0467

    Article  CAS  PubMed  Google Scholar 

  2. M. Terzolo, A. Stigliano, I. Chiodini, P. Loli, L. Furlani, G. Arnaldi et al. AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 164(6), 851–870 (2011). https://doi.org/10.1530/EJE-10-1147. Epub 2011 Apr 6

    Article  CAS  PubMed  Google Scholar 

  3. L.K. Nieman, B.M.K. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008). https://doi.org/10.1210/jc.2008-0125. Epub 2008 Mar 11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. M. Araujo-Castro, M.A. Sampedro Núñez, M. Marazuela, Autonomous cortisol secretion in adrenal incidentalomas. Endocrine 64(1), 1–13 (2019). https://doi.org/10.1007/s12020-019-01888-y. Epub 2019 Mar 7

    Article  CAS  PubMed  Google Scholar 

  5. A. Ruiz, T. Michalopoulou, A. Megia, S. Näf, I. Simón-Muela, E. Solano et al. Accuracy of new recommendations for adrenal incidentalomas in the evaluation of excessive cortisol secretion and follow-up. Eur. J. Clin. Investig. 49(2), e13048 (2019). https://doi.org/10.1111/eci.13048. Epub 2018 Dec 7

    Article  Google Scholar 

  6. M. Terzolo, A. Pia, G. Reimondo, Subclinical Cushing’s syndrome: definition and management. Clin. Endocrinol. 76(1), 12–18 (2012). https://doi.org/10.1111/j.1365-2265.2011.04253.x

    Article  CAS  Google Scholar 

  7. R. Rossi, L. Tauchmanova, A. Luciano, M. Di Martino, C. Battista, L. Del Viscovo et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85(4), 1440–1448 (2000)

    CAS  PubMed  Google Scholar 

  8. M. Terzolo, A. Pia, A. Ali, G. Osella, G. Reimondo, S. Bovio et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J. Clin. Endocrinol. Metab. 87(3), 998–1003 (2002)

    Article  CAS  Google Scholar 

  9. G. Di Dalmazi, V. Vicennati, E. Rinaldi, A.M. Morselli-Labate, E. Giampalma, C. Mosconi et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 166(4), 669–677 (2012). https://doi.org/10.1530/EJE-11-1039. Epub 2012 Jan 20

    Article  CAS  PubMed  Google Scholar 

  10. M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99(12), 4462–4470 (2014). https://doi.org/10.1210/jc.2014-3007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli, D.A. Thomas et al. Patients with apparently non-functioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99(8), 2754–2762 (2014). https://doi.org/10.1210/jc.2013-4064. Epub 2014 Apr 8

    Article  CAS  PubMed  Google Scholar 

  12. I. Chiodini, Clinical review: diagnosis and treatment of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 96(5), 1223–1236 (2011). https://doi.org/10.1210/jc.2010-2722. Epub 2011 Mar 2

    Article  CAS  PubMed  Google Scholar 

  13. I. Chiodini, V. Morelli, B. Masserini, A.S. Salcuni, C. Eller-Vainicher, R. Viti et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J. Clin. Endocrinol. Metab. 94(9), 3207–3214 (2009). https://doi.org/10.1210/jc.2009-0468. Epub 2009 Jun 23

    Article  CAS  PubMed  Google Scholar 

  14. M. Peppa, E. Boutati, C. Koliaki, N. Papaefstathiou, E. Garoflos, T. Economopoulos et al. Insulin resistance and metabolic syndrome in patients with non-functioning adrenal incidentalomas: A cause-effect relationship? Metabolism 59(10), 1435–1441 (2010). https://doi.org/10.1016/j.metabol.2010.01.007. Epub 2010 Feb 13

    Article  CAS  PubMed  Google Scholar 

  15. H. Yilmaz, N.B. Tütüncü, M. Şahin, Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J. Endocrinol. Investig. 32(11), 913–916 (2009). https://doi.org/10.3275/6431. Epub2009 Jul 14

    Article  CAS  Google Scholar 

  16. B. Masserini, V. Morelli, S. Bergamaschi, F. Ermetici, C. Eller-Vainicher, A.M. Barbieri et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur. J. Endocrinol. 160(1), 87–92 (2009). https://doi.org/10.1530/EJE-08-0485. Epub 2008 Oct 3

    Article  CAS  PubMed  Google Scholar 

  17. A. Tanabe, M. Naruse, T. Nishikawa, T. Yoshimoto, T. Shimizu, T. Seki et al. Autonomy of cortisol secretion in clinically silent adrenal incidentaloma. Horm. Metab. Res. 33(7), 444–450 (2001)

    Article  CAS  Google Scholar 

  18. A.S. Salcuni, V. Morelli, C.E. Vainicher, S. Palmieri, E. Cairoli, A. Spada et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur. J. Endocrinol. 174(3), 261–269 (2016). https://doi.org/10.1530/EJE-15-0977. Epub 2015 Dec 2

    Article  CAS  PubMed  Google Scholar 

  19. V. Morelli, B. Masserini, A.S. Salcuni, C. Eller-Vainicher, C. Savoca, R. Viti et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin. Endocrinol. 73(2), 161–166 (2010). https://doi.org/10.1111/j.1365-2265.2010.03794.x. Epub 2010 Feb 23

    Article  CAS  Google Scholar 

  20. Association American Diabetes., Updates to the standards of medical care in diabetes-2018. Diabetes Care. 41(9), 2045–2047 (2018). https://doi.org/10.2337/dc18-su09

    Article  CAS  Google Scholar 

  21. National Cholesterol Education Program (NCEP), Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 106(25), 3143–3421 (2002).

  22. B. Bulow, S. Jansson, C. Juhlin, L. Steen, M. Thoren, H. Wahrenberg et al. Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur. J. Endocrinol. 154(3), 419–423 (2006)

    Article  CAS  Google Scholar 

  23. R. Libe, C. Dall’Asta, L. Barbetta, A. Baccarelli, P. Beck-Peccoz, B. Ambrosi, Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147(4), 489–494 (2002)

    Article  CAS  Google Scholar 

  24. L. Barzon, N. Sonino, F. Fallo, G. Palù, M. Boscaro, Prevalence and natural history of adrenal incidentalomas. Eur. J. Endocrinol. 149(4), 273–285 (2003)

    Article  CAS  Google Scholar 

  25. J.W. Dobbie, Adrenocortical nodular hyperplasia: the ageing adrenal. J. Pathol. 99(1), 1–18 (1969)

    Article  CAS  Google Scholar 

  26. L. Papanastasiou, K. Alexandraki, I.I. Androulakis, S. Fountoulakis, T. Kounadi, A. Markou et al. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin. Endocrinol. 86(4), 488–498 (2017). https://doi.org/10.1111/cen.13294. Epub 2017 Jan 25

    Article  CAS  Google Scholar 

  27. J.M. Baena Díez, J.L. del Val García, J.T. Pelegrina, J.L. Martínez Martínez, R.M. Peñacoba, I.G. Tejón et al. Epidemiología de las enfermedades cardiovasculares y factores de riesgo en atención primaria. Rev. Esp. Cardiol. 58, 367–373 (2005). https://doi.org/10.1157/13073893. Vol. 58 Núm.04

    Article  PubMed  Google Scholar 

  28. J.A. Whitworth, G.J. Mangos, J.J. Kelly, Cushing, cortisol, and cardiovascular disease. Hypertension 36(5), 912–916 (2000)

    Article  CAS  Google Scholar 

  29. A.M. Isidori, C. Graziadio, R.M. Paragliola, A. Cozzolino, A.G. Ambrogio, A. Colao et al. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33(1), 44–60 (2015). https://doi.org/10.1097/HJH.0000000000000415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. D. Lopez, M.A. Luque-Fernandez, A. Steele, G.K. Adler, A. Turchin, A. Vaidya, “Nonfunctional” adrenal Tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann. Intern Med. 165(8), 533–542 (2016). https://doi.org/10.7326/M16-0547. Epub 2016 Aug 2

    Article  PubMed  PubMed Central  Google Scholar 

  31. G. Mazziotti, C. Gazzaruso, A. Giustina, Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 22(12), 499–506 (2011). https://doi.org/10.1016/j.tem.2011.09.001. Epub 2011 Oct 11

    Article  CAS  PubMed  Google Scholar 

  32. G.I. Sydney, K.J. Ioakim, S.A. Paschou, Insulin resistance and adrenal incidentalomas: a bidirectional relationship. Maturitas 121, 1–6 (2019). https://doi.org/10.1016/j.maturitas.2018.12.002. Epub 2018 Dec 5

    Article  CAS  PubMed  Google Scholar 

  33. A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, R. Vigneri, Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30(6), 586–623 (2009). https://doi.org/10.1210/er.2008-0047. Epub 2009 Sep 14

    Article  CAS  PubMed  Google Scholar 

  34. F. Peruzzi, M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol. Cell Biol. 19(10), 7203–7215 (1999)

    Article  CAS  Google Scholar 

  35. E. Nyman, G. Cedersund, P. Strålfors, Insulin signaling—mathematical modeling comes of age. Trends Endocrinol. Metab. 23(3), 107–115 (2012). https://doi.org/10.1016/j.tem.2011.12.007. Epub 2012 Jan 28

    Article  CAS  PubMed  Google Scholar 

  36. D. Ish-Shalom, G. Tzivion, C.T. Christoffersen, B. Ursø, P. De Meyts, D. Naor, Mitogenic potential of insulin on lymphoma cells lacking IGF‐1 receptor. Ann. N Y Acad. Sci. 766, 409–415 (1995)

    Article  CAS  Google Scholar 

  37. G. Di Dalmazi, V. Vicennati, S. Garelli, E. Casadio, E. Rinaldi, E. Giampalma et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2(5), 396–405 (2014). https://doi.org/10.1016/S2213-8587(13)70211-0. Epub 2014 Jan 29

    Article  PubMed  Google Scholar 

  38. L.F. Starker, J.W. Kunstman, T. Carling, Subclinical Cushing syndrome: a review. Surg. Clin. N. Am. 94(3), 657–668 (2014). https://doi.org/10.1016/j.suc.2014.02.008. Epub 2014 Apr 24

    Article  PubMed  Google Scholar 

  39. S. Tsagarakis, D. Vassiliadi, N. Thalassinos, Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J. Endocrinol. Investig. 29(5), 471–482 (2006)

    Article  CAS  Google Scholar 

  40. S. Kidambi, H. Raff, J.W. Findling, Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur. J. Endocrinol. 157(6), 725–731 (2007)

    Article  CAS  Google Scholar 

  41. S. Yener, H. Yilmaz, T. Demir, M. Secil, A. Comlekci, DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous? Endocrine 48(2), 669–676 (2015). https://doi.org/10.1007/s12020-014-0387-7. Epub 2014 Aug 22

    Article  CAS  PubMed  Google Scholar 

  42. G. Osella, M. Terzolo, G. Borretta, G. Magro, A. Ali, A. Piovesan et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J. Clin. Endocrinol. Metab. 79(6), 1532–1539 (1994)

    Article  CAS  Google Scholar 

  43. Z. Bencsik, I. Szabolcs, Z. Kovács, A. Ferencz, A. Vörös, I. Kaszás et al. Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. J. Clin. Endocrinol. Metab. 81(5), 1726–1729 (1996)

    CAS  PubMed  Google Scholar 

  44. I. Ilias, A. Sahdev, R.H. Reznek, A.B. Grossman, K. Pacak, The optimal imaging of adrenal tumours: a comparison of different methods. Endocr. Relat. Cancer 14(3), 587–599 (2007)

    Article  Google Scholar 

  45. S. Yener, S. Ertilav, M. Secil, B. Akinci, T. Demir, L. Kebapcilar et al. Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with non-functioning adrenal adenomas. Med. Princ. Pract. 21(5), 429–434 (2012). https://doi.org/10.1159/000336589. Epub 2012 Mar 2

    Article  CAS  PubMed  Google Scholar 

  46. V. Morelli, G. Reimondo, R. Giordano, S. Della Casa, C. Policola, S. Palmieri et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J. Clin. Endocrinol. Metab. 99(3), 827–834 (2014). https://doi.org/10.1210/jc.2013-3527. Epub 2014 Jan 1

    Article  CAS  PubMed  Google Scholar 

  47. L. Barzon, C. Scaroni, N. Sonino, F. Fallo, A. Paoletta, M. Boscaro, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84(2), 520–526 (1999)

    CAS  PubMed  Google Scholar 

  48. L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146(1), 61–66 (2002)

    Article  CAS  Google Scholar 

  49. V. Morelli et al. Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Investig. 40(9), 803–811 (2010). https://doi.org/10.1111/j.1365-2362.2010.02330.x

    Article  CAS  Google Scholar 

  50. V. Morelli et al. Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. Eur. J. Endocrinol. 177(1), 73–83 (2017). https://doi.org/10.1530/EJE-17-0047

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Department, Ramón y Cajal University Hospital, Madrid, Spain

    Marta Araujo-Castro

  2. Endocrinology Department, Salamanca Clinical University Hospital, Salamanca, Spain

    Cristina Robles Lázaro

  3. Endocrinology Department, La Paz University Hospital, Madrid, Spain

    Paola Parra Ramírez

  4. Endocrinology Department, San Carlos Clinical University Hospital, Madrid, Spain

    Martín Cuesta Hernández

  5. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain

    Martín Cuesta Hernández

  6. Endocrinology Department, Princesa University Hospital, Madrid, Spain

    Miguel Antonio Sampedro Núñez & Mónica Marazuela

Authors
  1. Marta Araujo-Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Robles Lázaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Parra Ramírez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martín Cuesta Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miguel Antonio Sampedro Núñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mónica Marazuela
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta Araujo-Castro.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Araujo-Castro, M., Robles Lázaro, C., Parra Ramírez, P. et al. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?. Endocrine 66, 650–659 (2019). https://doi.org/10.1007/s12020-019-02066-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-019-02066-w

Keywords

Search

Navigation